Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October

Rhea-AI Summary

Precision BioSciences (Nasdaq: DTIL), a clinical-stage biotechnology company, announced its participation in two virtual investor conferences on October 5, 2020. The conferences include the Chardan 4th Annual Genetic Medicines Conference, scheduled for 8:30 AM ET, and the Jefferies Cell Therapy Summit, starting at 5:30 PM ET. Live webcasts will be accessible on the company’s website, with archived replays available for 30 days post-event. Precision BioSciences utilizes its ARCUS genome editing platform to develop innovative therapies for genetic and infectious diseases.

DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS^® genome editing platform, today announced its participation in the following upcoming virtual investor conferences:

• Chardan 4^th Annual Genetic Medicines Conference
  Date: Monday, October 5, 2020
  Time: 8:30 – 9:00 AM ET
  
  
• Jefferies Cell Therapy Summit
  Date: October 5, 2020
  Time: 5:30 – 6:00 PM ET

Live webcasts of each presentation will be accessible on the Company’s website www.precisionbiosciences.com, under the Investors & Media section. An archived replay of the webcasts will be available for approximately 30 days following the presentations.

About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS^® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

Investor and Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
maurissa.messier@precisionbiosciences.com

Josh Rappaport
Stern Investor Relations
josh.rappaport@sternir.com

 

FAQ

What are the details of Precision BioSciences' upcoming events?

Precision BioSciences will participate in two virtual conferences on October 5, 2020: the Chardan 4th Annual Genetic Medicines Conference at 8:30 AM ET and the Jefferies Cell Therapy Summit at 5:30 PM ET.

Where can I watch the webcasts for the Precision BioSciences conferences?

Live webcasts of the presentations will be available on Precision BioSciences' website under the Investors & Media section.

How long will the webcasts from the Precision BioSciences conferences be available?

The archived replays of the webcasts will be accessible for approximately 30 days following the presentations.

What is the focus of Precision BioSciences' research and development?

Precision BioSciences focuses on developing allogeneic CAR T and in vivo gene correction therapies using its proprietary ARCUS genome editing platform.

What is the stock symbol for Precision BioSciences?

The stock symbol for Precision BioSciences is DTIL.